Promising data were reported in a PDX model resistant to tamoxifen and fulvestrant plus palbociclib with ESR1-E380Q and PIK3CA-E545K/E722K, in which tumor growth was inhibited by elacestrant and even more so with elacestrant combined with everolimus [51]. This evidence concerns the gene ESR1 and neoplasm.